Old School Investor ๐Ÿ’Ž (@watcherstock) 's Twitter Profile
Old School Investor ๐Ÿ’Ž

@watcherstock

Individual investor, tweets are personal and no investment advice!

ID: 1568717796

calendar_today04-07-2013 18:08:22

5,5K Tweet

530 Takipรงi

106 Takip Edilen

Dexter (@dexter1capital) 's Twitter Profile Photo

$HFG 1/ A lot of smart investors say the same thing right now: โ€œI believe in HFG turnaround in 2026, but I dont see any near term triggers - so I'd rather rotate into something else.โ€ Fair. But I think that logic, while elegant, is actually dangerous in deep-value turnarounds.

Old School Investor ๐Ÿ’Ž (@watcherstock) 's Twitter Profile Photo

So short term growth Soitec trimmed down al little because of inventory decline in Mobileโ€ฆ Share responds with -30% as if it was a hyperscaler. EV /EBITDA24 is just 4x ๐Ÿ˜‚ Massive exaggeration, bought more $SOI.PA ๐Ÿš€

Tech Fund (@techfund1) 's Twitter Profile Photo

Deutsche buy thesis on $ADYEN: "Adyen has demonstrated a remarkable growth trajectory, scaling its payments volume from E32b in 2015 to over E1.3tr today, representing a 45% CAGR over the last decade. This 40x increase in volume has driven significant market share gains and sets

Atos (@atos) 's Twitter Profile Photo

Many organizations launch successful pilotsโ€”then hit a wall. Why? Because operationalizing AI requires a shift in mindset, investment, and accountability. This new white paper by Harvard Business Review, in association with us, lays out how to. ๐Ÿ‘‰ lbr.io/s/vQQwMf

Many organizations launch successful pilotsโ€”then hit a wall. Why? Because operationalizing AI requires a shift in mindset, investment, and accountability.

This new white paper by Harvard Business Review, in association with us, lays out how to.

๐Ÿ‘‰ lbr.io/s/vQQwMf
Wall St Engine (@wallstengine) 's Twitter Profile Photo

BofA on $ASML (Buy): "We met with ASML CEO Christophe Fouquet & Investor Relations lead Marcel Kemp. Our key takeaways are: 1. In DRAM, demand is outstripping supply, with strong orders expected over the next few quarters for 2027 capacity additions. EUV layers are increasing

BofA on $ASML (Buy):

"We met with ASML CEO Christophe Fouquet & Investor Relations lead Marcel Kemp. Our key takeaways are:

1. In DRAM, demand is outstripping supply, with strong orders expected over the next few quarters for 2027 capacity additions. EUV layers are increasing
Investseekers (@investseekers) 's Twitter Profile Photo

Deutsche Bank reiterates its Buy rating on $NVO, with analyst Emmanuel Papadakis maintaining a target price of DKK 475. #StockMarket #Investing

Jordy Beuving (@beuvingjordy) 's Twitter Profile Photo

Seems like investors (finally) realize semiconductor equipment companies actually do benefit from increased memory chip demand ๐Ÿ˜ Sometimes all you need to do is watch what's happening in the sector, use common sense & be patient All upgrades by equity analysts long overdue ๐Ÿ“ˆ

Jordy Beuving (@beuvingjordy) 's Twitter Profile Photo

๐ŸŒ โœ… ๐Ÿ“ˆ ๐Ÿš€ Needham $BESI Top Pick โ‚ฌ190 PT The firm upgraded BE Semiconductor to Buy from Hold, put a โ‚ฌ190 price target, named BESI as its top pick for 2026 and added it to its Needham Conviction List. seekingalpha.com/news/4536964-cโ€ฆ

Old School Investor ๐Ÿ’Ž (@watcherstock) 's Twitter Profile Photo

Good to see $NVO moving up ๐Ÿ“ˆ after successful oral Ozempic launch Would not be surprised to see it moving back to DKK750+ / $100+ (Still just half of value Lilly)

Jordy Beuving (@beuvingjordy) 's Twitter Profile Photo

๐ŸŒ โœ… ๐Ÿ“ˆ ๐Ÿ‘‡ For those still wondering why semi equip is outperforming $TEL CapEx raise +48% to record high [News] Tokyo Electron Reportedly Raises FY26 CapEx 48% to Record High, Bets on DRAM Etching Demand buff.ly/FSFlm8I

The Analyst (@mmatters22596) 's Twitter Profile Photo

The valuation gap between $LLY and $NVO has to be the dumbest thing I've seen this year. Novo Nordisk: $16 B net profit Eli Lilly: $18 B net profit The exact same business model and segment, nearly the same size. Eli Lilly is just slightly bigger and grows a little bit faster.

The valuation gap between $LLY and $NVO has to be the dumbest thing I've seen this year.

Novo Nordisk: $16 B net profit
Eli Lilly: $18 B net profit

The exact same business model and segment, nearly the same size. Eli Lilly is just slightly bigger and grows a little bit faster.
Investseekers (@investseekers) 's Twitter Profile Photo

$NVO says interest in its new once-daily Wegovy pill is โ€œtremendousโ€ just days after launch. U.S. head Dave Moore says many patients had stayed on the sidelines simply because they didnโ€™t want injections, and are now entering treatment for the first time. Takeaway: this isnโ€™t